IN2012DN01292A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01292A
IN2012DN01292A IN1292DEN2012A IN2012DN01292A IN 2012DN01292 A IN2012DN01292 A IN 2012DN01292A IN 1292DEN2012 A IN1292DEN2012 A IN 1292DEN2012A IN 2012DN01292 A IN2012DN01292 A IN 2012DN01292A
Authority
IN
India
Prior art keywords
therapy
preparing
processes
compound
formula
Prior art date
Application number
Other languages
English (en)
Inventor
Simon Craig Andrew
Zarah Ismail Salima
Maxwell Lawrence Ronnie
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of IN2012DN01292A publication Critical patent/IN2012DN01292A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IN1292DEN2012 2009-08-27 2010-08-25 IN2012DN01292A (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23743509P 2009-08-27 2009-08-27
PCT/EP2010/062420 WO2011023733A1 (en) 2009-08-27 2010-08-25 Anhydrate forms of a pyridine derivative

Publications (1)

Publication Number Publication Date
IN2012DN01292A true IN2012DN01292A (hu) 2015-06-05

Family

ID=42790943

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1292DEN2012 IN2012DN01292A (hu) 2009-08-27 2010-08-25

Country Status (18)

Country Link
US (1) US8796269B2 (hu)
EP (1) EP2470545B1 (hu)
JP (3) JP2013503134A (hu)
KR (1) KR20120056258A (hu)
CN (1) CN102639536B (hu)
AU (1) AU2010288502B2 (hu)
BR (1) BR112012003435A2 (hu)
CA (1) CA2772168C (hu)
DK (1) DK2470545T3 (hu)
EA (1) EA021411B1 (hu)
ES (1) ES2440938T3 (hu)
IL (1) IL217922A (hu)
IN (1) IN2012DN01292A (hu)
MX (1) MX2012002369A (hu)
PL (1) PL2470545T3 (hu)
SG (1) SG178231A1 (hu)
WO (1) WO2011023733A1 (hu)
ZA (1) ZA201200812B (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA021411B1 (ru) * 2009-08-27 2015-06-30 Нерр Терапьютикс Лимитед Безводная форма производного пиридина
EP3160469B1 (en) * 2014-06-25 2021-04-28 Emory University Methods of managing conditioned fear with neurokinin receptor antagonists
ES2753539T3 (es) * 2015-05-18 2020-04-13 Nerre Therapeutics Ltd Antagonista del receptor NK-1/NK-3 para el tratamiento de los sofocos
JP7110197B2 (ja) * 2016-12-15 2022-08-01 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Nrf2アクチベーター
SI3765024T1 (sl) * 2018-03-14 2024-05-31 KaNDy Therapeutics Limited Nova farmacevtska formulacija, ki vsebuje dvojne antagoniste receptorja NK-1/NK-3
WO2021030335A1 (en) * 2019-08-12 2021-02-18 Millendo Therapeutics, Inc. A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof
CN118496152A (zh) 2019-11-15 2024-08-16 康堤医疗有限公司 制备nt-814的关键中间体6-氯-4-(4-氟-2-甲基苯基)吡啶-3-胺的新化学方法
EP4431512A1 (en) 2023-03-16 2024-09-18 Bayer Consumer Care AG Novel dual nk-1/nk-3 receptor antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1035115B1 (en) * 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
NZ541243A (en) * 2003-01-31 2008-04-30 Hoffmann La Roche New crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1lambda6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
DE602004008631T2 (de) * 2003-07-03 2008-07-10 F. Hoffmann-La Roche Ag Duale nk1/nk3 antagonisten zur behandlung von schizophrenie
WO2007028654A1 (en) * 2005-09-09 2007-03-15 Smithkline Beecham Corporation Pyridine derivatives and their use in the treatment of psychotic disorders
AU2008346110A1 (en) * 2007-12-11 2009-07-16 Cipla Ltd. Crystalline polymorphic forms of zopiclone, processes for their preparation and their pharmaceutical compositions
GB0814340D0 (en) * 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
EA021411B1 (ru) * 2009-08-27 2015-06-30 Нерр Терапьютикс Лимитед Безводная форма производного пиридина
JP6342662B2 (ja) * 2014-01-29 2018-06-13 京セラ株式会社 ドリルおよびそれを用いた切削加工物の製造方法

Also Published As

Publication number Publication date
ZA201200812B (en) 2013-03-27
JP2016000739A (ja) 2016-01-07
EP2470545B1 (en) 2013-10-09
CA2772168A1 (en) 2011-03-03
EA201270302A1 (ru) 2012-07-30
IL217922A0 (en) 2012-03-29
JP2017193564A (ja) 2017-10-26
US20120157450A1 (en) 2012-06-21
PL2470545T3 (pl) 2014-03-31
AU2010288502A1 (en) 2012-02-23
BR112012003435A2 (pt) 2016-02-23
KR20120056258A (ko) 2012-06-01
CN102639536B (zh) 2015-03-18
WO2011023733A1 (en) 2011-03-03
CN102639536A (zh) 2012-08-15
IL217922A (en) 2016-06-30
EP2470545A1 (en) 2012-07-04
SG178231A1 (en) 2012-03-29
MX2012002369A (es) 2012-03-29
AU2010288502B2 (en) 2013-12-12
DK2470545T3 (da) 2014-01-13
ES2440938T3 (es) 2014-01-31
JP2013503134A (ja) 2013-01-31
CA2772168C (en) 2019-01-08
US8796269B2 (en) 2014-08-05
EA021411B1 (ru) 2015-06-30
JP6404186B2 (ja) 2018-10-10

Similar Documents

Publication Publication Date Title
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
MY149731A (en) Compounds
NZ608116A (en) Triazine-oxadiazoles
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
IN2012DN01292A (hu)
MX2012013274A (es) Novedosos derivados de la pirimidina.
MX2010002461A (es) (carboxilalquilenfenil)feniloxamidas, metodo para su produccion y uso de las mismas como medicamento.
IN2014CN04530A (hu)
IN2012DN03182A (hu)
MX2010002419A (es) (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
MY187718A (en) Pharmaceutical formulations
IN2012DN02139A (hu)
MX2013010898A (es) Novedoso derivados de la pirimidina.
MX2010002210A (es) Derivados de catecolamina y profarmacos de los mismos.
IN2015DN01119A (hu)
MX2011011776A (es) Nuevos profarmacos de triptolite.
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
UA110128C2 (uk) Індолкарбоксаміди та бензімідазолкарбоксаміди як інсектициди та акарициди
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
MX2012007253A (es) Derivados triciclicos y sus usos y composiciones farmaceuticas.
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
IN2012DN02698A (hu)
MX2011008126A (es) Compuestos de indol sustituidos como moduladores del receptor 1 de bradiquinina.